Clinical management of CRC is still based on TNM classification for therapeutic decisions, and APC11 protein expression may thus provide a novel, cost-effective, immunohistochemistry-based means of improving personalized therapeutic strategies. The gene discussed is ANAPC11; the disease is colorectal carcinoma.